<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014936</url>
  </required_header>
  <id_info>
    <org_study_id>EMR200095_001</org_study_id>
    <nct_id>NCT01014936</nct_id>
  </id_info>
  <brief_title>First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor MSC2156119J Under Three Different Regimens in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore
      MSC2156119J, in subjects with advanced solid tumors who have not responded to previous
      therapies or for whom no other therapies are available.

      Subjects will be assigned one of the dosing regimens:

        -  Regimen 1: MSC2156119J once daily for 14 days, followed by 7 days with no treatment
           (21-day cycle)

        -  Regimen 2: MSC2156119J three times per week (e.g., Days 1, 3, and 5) for three weeks
           (21-day cycle)

        -  Regimen 3: MSC2156119J every day for three weeks (21-day cycle)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2009</start_date>
  <completion_date type="Actual">October 31, 2015</completion_date>
  <primary_completion_date type="Actual">October 31, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Any Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Day 1, 3, 8, 14, 17 of Cycle 1 (for Regimen 1 and 3); Day 1, 3, 8, 15, 19 of Cycle 1 (for Regimen 2)</time_frame>
    <description>DLT was defined as one of the following adverse events (AEs) observed during Cycle1, regardless of MSC2156119J relationship, excluding AEs assessed by investigator exclusively related to subject's underlying disease or medical condition: Grade 4 neutropenia for &gt;7 days; Grade &gt;=3 febrile neutropenia for &gt;1 day; Grade 4 thrombocytopenia/Grade 3 with bleeding; Grade &gt;=3 nausea and emesis, despite optimal treatment; Grade &gt;=3 non-hematological AE, except emesis and nausea with no adequate therapy and alopecia, Grade &gt;= 3 liver AE with a recovery period of &gt;7 days or to Grade &lt;=1 for subjects without liver metastases or to &lt;=2 for subjects with liver metastases; Grade &gt;=3 lipase and/or amylase rise with pancreatitis confirmation, either based on clinical or radiological signs. Any AE not otherwise defined as a DLT that, due to prolonged recovery to Grade &lt;=1 or baseline status, leads to delay of above 21 days in planned administration of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Cycle 1 (Day 1 to Day 21)</time_frame>
    <description>MTD was defined as the dose level at which 2 out of 3 subjects or 2 out of 6 subjects experienced a DLT. The primary endpoint was to determine MTD of MSC2156119J for each of the 3 treatment regimens in subjects with advanced solid tumors. However, during the course of the trial it was established that the MTD could not be determined and instead, RP2D was to be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Treatment-Related Adverse Events</measure>
    <time_frame>Baseline up to 158.01 weeks</time_frame>
    <description>Related AE was defined as any untoward medical occurrence which was considered to have a relationship with the study drug (suspected to be reasonably related to the study drug or AE was medically (pharmacologically/clinically) attributed to the study drug as per Investigator's assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-Emergent AEs (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death</measure>
    <time_frame>Baseline up to 158.01 weeks</time_frame>
    <description>AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 33 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Plasma Concentration (Cmax) After Single Dose of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Plasma Concentration (Cmax) After Single Dose of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Plasma Concentration (Cmax) After Single Dose of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Plasma Concentration (Cmax) After Multiple Dose of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Plasma Concentration (Cmax) After Multiple Dose of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 19 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Plasma Concentration (Cmax) After Multiple Dose of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
    <description>Reporting group &quot;MSC2156119J 1200 mg: Fasted&quot; is not applicable for Multiple Dosing because only one subject was erroneously dosed with 1200 mg in fasted state as a single dose in Regimen 3. For multiple dose PK profile (Study Day 14), this subject was included in reporting group &quot;MSC2156119J 1400 mg: Fed&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Reach Maximum Plasma Concentration (Tmax) After Single Dose of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Reach Maximum Plasma Concentration (Tmax) After Single Dose of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24, 48, 49.32 hours post-dose on Day 1 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Reach Maximum Plasma Concentration (Tmax) After Single Dose of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Reach Maximum Plasma Concentration (Tmax) After Multiple Dose of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Reach Maximum Plasma Concentration (Tmax) After Multiple Dose of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 19 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Reach Maximum Plasma Concentration (Tmax) After Multiple Dose of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
    <description>Reporting group &quot;MSC2156119J 1200 mg: Fasted&quot; is not applicable for Multiple Dosing because only one subject was erroneously dosed with 1200 mg in fasted state as a single dose in Regimen 3. For multiple dose PK profile (Study Day 14), this subject was included in reporting group &quot;MSC2156119J 1400 mg: Fed&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life ( t1/2) After Single Dose Of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Apparent Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life ( t1/2) After Single Dose Of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Apparent Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life ( t1/2) After Single Dose Of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Apparent Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) After Multiple Dose Of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
    <description>Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) After Multiple Dose Of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 19 Cycle 1</time_frame>
    <description>Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) After Multiple Dose Of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
    <description>Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Versus Time Curve From Time Zero to Last Sampling Time (AUC0-t) After First Dose of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After First Dose of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After First Dose of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After Multiple Dose of MSC2156119J : Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After Multiple Dose of MSC2156119J : Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 19 Cycle 1</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After Multiple Dose of MSC2156119J : Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. Reporting group &quot;MSC2156119J 1200 mg: Fasted&quot; is not applicable for Multiple Dosing because only one subject was erroneously dosed with 1200 mg in fasted state as a single dose in Regimen 3. For multiple dose PK profile (Study Day 14), this subject was included in reporting group &quot;MSC2156119J 1400 mg: Fed&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) After Single Dose Of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) After Single Dose Of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) After Single Dose Of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Single Dose of MSC2156119: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Single Dose of MSC2156119: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24, 48 hours post-dose on Day 1 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Single Dose of MSC2156119: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Multiple Dose of MSC2156119: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Multiple Dose of MSC2156119: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24, 48 hours post-dose on Day 19 Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Multiple Dose of MSC2156119: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
    <description>Reporting group &quot;MSC2156119J 1200 mg: Fasted&quot; is not applicable for Multiple Dosing because only one subject was erroneously dosed with 1200 mg in fasted state as a single dose in Regimen 3. For multiple dose PK profile (Study Day 14), this subject was included in reporting group &quot;MSC2156119J 1400 mg: Fed&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Body Clearance (CL/f) After First Dose of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0−inf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Body Clearance (CL/f) After First Dose of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0−inf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Body Clearance (CL/f) After First Dose of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0−inf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/f) After First Dose of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/f) After First Dose of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/f) After First Dose of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/f) After Multiple Dose of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
    <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/f) After Multiple Dose of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 19 Cycle 1</time_frame>
    <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/f) After Multiple Dose of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
    <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Rate Constant (λz) After Single Dose of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Rate Constant (λz) After Single Dose of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Rate Constant (λz) After Single Dose of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
    <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Rate Constant (λz) After Multiple Dose of MSC2156119J: Regimen 1</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
    <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Rate Constant (λz) After Multiple Dose of MSC2156119J: Regimen 2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 19 Cycle 1</time_frame>
    <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Rate Constant (λz) After Multiple Dose of MSC2156119J: Regimen 3</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
    <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Cytoplasm and Membrane H-Score at Day 1 Cycle 2</measure>
    <time_frame>Baseline, Day 1 Cycle 2</time_frame>
    <description>Histo score (H-score) is a composite score that comprises of intensity and percentage of staining and is used for assessing the amount of protein or phospho-protein present in a biopsy sample. The composite score obtained by H-score is derived by summing the percentages of cell staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+; where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). The composite H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change From Baseline in Cytoplasm and Membrane H-Score at Day 1 Cycle 2</measure>
    <time_frame>Baseline, Day 1 Cycle 2</time_frame>
    <description>Histo score (H-score) is a composite score that comprises of intensity and percentage of staining and is used for assessing the amount of protein or phospho-protein present in a biopsy sample. The composite score obtained by H-score is derived by summing the percentages of cell staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+; where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). The composite H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein. Fold change = on-treatment value/ baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Monovalent Antagonist Antibody to Receptor MET (MetMAb) Score (MMS)</measure>
    <time_frame>Day 1 Cycle 2</time_frame>
    <description>MetMAb score was used to assess the tumor c-Met expression and ranged from 0 to 3, where a score of 0 corresponds to the lowest c-Met expression and a score of 3 corresponds to the highest c-Met expression in tumor tissue by immunohistochemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Percentage Change In Sum of Longest Diameter (SOLD) of Target Lesions to Post-Baseline Nadir</measure>
    <time_frame>Baseline, On Treatment (up to 153.3 weeks)</time_frame>
    <description>The post-baseline nadir was defined as the the smallest SOLD recorded after baseline. The relative change (%) was derived based on the SOLD of target lesions as follows: 100* (SOLD at post-baseline nadir - baseline SOLD) / baseline SOLD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Best Overall Response (BOR)</measure>
    <time_frame>Baseline up to 153.3 weeks</time_frame>
    <description>Number of subjects with BOR in each category (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD]) according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) was reported. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. PD:defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Baseline up to 153.3 weeks</time_frame>
    <description>PFS was defined as the time (in months) between the first dosing day and radiographic PD or clinical PD (as recorded on the study termination form) or death, if death occurred within 12 weeks (84 days) after the last tumor assessment without documented progressive disease, whichever occurred first. Any subject with neither assessment of tumor progression, nor death within 12 weeks after last tumor assessment date was censored on the date of last tumor assessment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available</condition>
  <arm_group>
    <arm_group_label>MSC2156119J Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSC2156119J Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSC2156119J Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSC2156119J</intervention_name>
    <arm_group_label>MSC2156119J Regimen 1</arm_group_label>
    <arm_group_label>MSC2156119J Regimen 2</arm_group_label>
    <arm_group_label>MSC2156119J Regimen 3</arm_group_label>
    <other_name>EMD 1214063</other_name>
    <other_name>Tepotinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject should read and fully understand the requirements of the trial, be willing to
             comply with all trial visits and assessments, and be willing and able to give informed
             consent

          2. Histologically or cytologically confirmed solid tumor, either refractory to standard
             therapy or for which no effective standard therapy is available

          3. Measurable or evaluable disease, as defined by RECIST 1.0

          4. Estimated life expectancy greater than (&gt;) three months

          5. Men or women aged greater than or equal to (&gt;=) 18 years

          6. Women of childbearing potential must have a negative blood pregnancy test at the
             Screening Visit. For this trial, women of childbearing potential are defined as all
             women after puberty, unless they are post-menopausal for at least 12 months, are
             surgically sterile, or are sexually inactive.

          7. Subjects and their partners must be willing to avoid pregnancy during the trial and
             until three months after the last trial treatment. Male subjects with female partners
             of childbearing potential and female subjects of childbearing potential must,
             therefore, be willing to use adequate contraception as approved by the investigator,
             such as a two-barrier method or one-barrier method with spermicide or intrauterine
             device. This requirement begins two weeks before receiving the first trial treatment
             and ends one month after receiving the last treatment.

          8. ECOG performance status of 0 to 2

          9. Adequate hematological function:

               -  Hemoglobin &gt;= 9.0 g/dL

               -  Neutrophils &gt; 1.5 x 109/L

               -  Platelets &gt;= 75 x 109/L

         10. Adequate liver function:

               -  Total bilirubin less than or equal to (&lt;=) 1.5 x ULN (upper limit to normal)

               -  AST/ ALT ≤ 2.5 x ULN

             For subjects with liver metastases:

               -  Total bilirubin ≤ 1.5 x ULN

               -  AST/ ALT ≤ 5 x ULN

         11. Adequate renal function:

               -  Serum creatinine &lt; 1.5 x ULN, and/or

               -  Calculated creatinine clearance &gt; 60 mL/min

         12. Resolution of all acute chemotherapy, radiotherapy or surgery-related AEs to Grade &lt;=
             2, except for alopecia

         13. Recovery from any surgical intervention

         14. Subjects enrolling after the MTD has been determined must present specific c Met
             alterations (mutation, overexpression, amplification

        Exclusion Criteria:

          1. Received chemotherapy, immunotherapy, hormonal therapy (except subjects with prostate
             cancer), biologic therapy, or any other investigational agent or anticancer therapy
             within 28 days (or five half-lives for non-cytotoxics, whichever is shorter), of Day 1
             of trial treatment (six weeks for nitrosureas or mitomycin C)

          2. Received extensive prior radiotherapy on more than 30% of bone marrow

          3. Symptomatic primary tumors or metastasis of brain and/or central nervous system,
             uncontrolled with antiepileptics and requiring high doses of steroids

          4. Known HIV positivity, active hepatitis C, or active hepatitis B

          5. Medical history of liver fibrosis/ cirrhosis

          6. Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family
             members who suffer(ed) from such

          7. Medical history of difficulty swallowing, malabsorption or other chronic
             gastrointestinal disease, or conditions that may hamper compliance and/or absorption
             of the tested product

          8. Medical history of surgery within six weeks prior to enrollment

          9. Impaired cardiac function (left ventricular ejection fraction &lt; 45% defined by
             echocardiograph, serious arrhythmia, unstable angina pectoris, congestive heart
             failure NYHA III and IV, myocardial infarction within the last 12 months prior to
             trial entry; signs of pericardial effusion)

         10. Hypertension uncontrolled by standard therapies (not stabilized to 150/90 mm Hg)

         11. Peripheral neuropathy Grade &gt;= 2

         12. Medical history of any other significant medical disease, major surgery, or
             psychiatric condition that might impair the subject's well being or preclude full
             participation in the trial

         13. Women who are pregnant or nursing

         14. Known drug abuse or alcohol abuse

         15. Participation in another clinical trial within the past 28 days

         16. Requires concurrent treatment with a non-permitted drug

         17. Known hypersensitivity to any of the trial treatment ingredients

         18. Legal incapacity or limited legal capacity

         19. Any other reason that, in the opinion of the principal investigator, precludes the
             subject from participating in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <results_first_submitted>October 14, 2016</results_first_submitted>
  <results_first_submitted_qc>March 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2017</results_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>advanced solid tumors</keyword>
  <keyword>refractory to standard therapy</keyword>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>First/last subject (informed consent): November 2009/December 2014. Last subject completed: October 2015. Clinical data cut-off: February 2016</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MSC2156119J Regimen 1</title>
          <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
        </group>
        <group group_id="P2">
          <title>MSC2156119J Regimen 2</title>
          <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
        </group>
        <group group_id="P3">
          <title>MSC2156119J Regimen 3</title>
          <description>Subjects were administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>MSC2156119J Regimen 1</title>
          <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
        </group>
        <group group_id="B2">
          <title>MSC2156119J Regimen 2</title>
          <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
        </group>
        <group group_id="B3">
          <title>MSC2156119J Regimen 3</title>
          <description>Subjects were administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.97" spread="13.496"/>
                    <measurement group_id="B2" value="59.29" spread="14.656"/>
                    <measurement group_id="B3" value="56.49" spread="13.986"/>
                    <measurement group_id="B4" value="58.32" spread="14.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Dose Limiting Toxicity (DLT)</title>
        <description>DLT was defined as one of the following adverse events (AEs) observed during Cycle1, regardless of MSC2156119J relationship, excluding AEs assessed by investigator exclusively related to subject’s underlying disease or medical condition: Grade 4 neutropenia for &gt;7 days; Grade &gt;=3 febrile neutropenia for &gt;1 day; Grade 4 thrombocytopenia/Grade 3 with bleeding; Grade &gt;=3 nausea and emesis, despite optimal treatment; Grade &gt;=3 non-hematological AE, except emesis and nausea with no adequate therapy and alopecia, Grade &gt;= 3 liver AE with a recovery period of &gt;7 days or to Grade &lt;=1 for subjects without liver metastases or to &lt;=2 for subjects with liver metastases; Grade &gt;=3 lipase and/or amylase rise with pancreatitis confirmation, either based on clinical or radiological signs. Any AE not otherwise defined as a DLT that, due to prolonged recovery to Grade &lt;=1 or baseline status, leads to delay of above 21 days in planned administration of study drug.</description>
        <time_frame>Day 1, 3, 8, 14, 17 of Cycle 1 (for Regimen 1 and 3); Day 1, 3, 8, 15, 19 of Cycle 1 (for Regimen 2)</time_frame>
        <population>DLT analysis set comprised of subjects who had either completed Cycle 1 or had stopped treatment because of a DLT during Cycle 1.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J Regimen 1</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J Regimen 2</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J Regimen 3</title>
            <description>Subjects were administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Dose Limiting Toxicity (DLT)</title>
          <description>DLT was defined as one of the following adverse events (AEs) observed during Cycle1, regardless of MSC2156119J relationship, excluding AEs assessed by investigator exclusively related to subject’s underlying disease or medical condition: Grade 4 neutropenia for &gt;7 days; Grade &gt;=3 febrile neutropenia for &gt;1 day; Grade 4 thrombocytopenia/Grade 3 with bleeding; Grade &gt;=3 nausea and emesis, despite optimal treatment; Grade &gt;=3 non-hematological AE, except emesis and nausea with no adequate therapy and alopecia, Grade &gt;= 3 liver AE with a recovery period of &gt;7 days or to Grade &lt;=1 for subjects without liver metastases or to &lt;=2 for subjects with liver metastases; Grade &gt;=3 lipase and/or amylase rise with pancreatitis confirmation, either based on clinical or radiological signs. Any AE not otherwise defined as a DLT that, due to prolonged recovery to Grade &lt;=1 or baseline status, leads to delay of above 21 days in planned administration of study drug.</description>
          <population>DLT analysis set comprised of subjects who had either completed Cycle 1 or had stopped treatment because of a DLT during Cycle 1.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase 2 Dose (RP2D)</title>
        <description>MTD was defined as the dose level at which 2 out of 3 subjects or 2 out of 6 subjects experienced a DLT. The primary endpoint was to determine MTD of MSC2156119J for each of the 3 treatment regimens in subjects with advanced solid tumors. However, during the course of the trial it was established that the MTD could not be determined and instead, RP2D was to be determined.</description>
        <time_frame>Cycle 1 (Day 1 to Day 21)</time_frame>
        <population>DLT analysis set comprised of subjects who had either completed Cycle 1 or had stopped treatment because of a DLT during Cycle 1.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J Combined</title>
            <description>All subjects who were administered with micronized or non-micronized MSC2156119J (capsule or tablet formulation) in any of the three regimens.</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase 2 Dose (RP2D)</title>
          <description>MTD was defined as the dose level at which 2 out of 3 subjects or 2 out of 6 subjects experienced a DLT. The primary endpoint was to determine MTD of MSC2156119J for each of the 3 treatment regimens in subjects with advanced solid tumors. However, during the course of the trial it was established that the MTD could not be determined and instead, RP2D was to be determined.</description>
          <population>DLT analysis set comprised of subjects who had either completed Cycle 1 or had stopped treatment because of a DLT during Cycle 1.</population>
          <units>milligram</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Treatment-Related Adverse Events</title>
        <description>Related AE was defined as any untoward medical occurrence which was considered to have a relationship with the study drug (suspected to be reasonably related to the study drug or AE was medically (pharmacologically/clinically) attributed to the study drug as per Investigator’s assessment.</description>
        <time_frame>Baseline up to 158.01 weeks</time_frame>
        <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J Regimen 1</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J Regimen 2</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J Regimen 3</title>
            <description>Subjects were administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-Related Adverse Events</title>
          <description>Related AE was defined as any untoward medical occurrence which was considered to have a relationship with the study drug (suspected to be reasonably related to the study drug or AE was medically (pharmacologically/clinically) attributed to the study drug as per Investigator’s assessment.</description>
          <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-Emergent AEs (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death</title>
        <description>AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 33 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs.</description>
        <time_frame>Baseline up to 158.01 weeks</time_frame>
        <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J Regimen 1</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J Regimen 2</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J Regimen 3</title>
            <description>Subjects were administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-Emergent AEs (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death</title>
          <description>AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 33 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs.</description>
          <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs Leading To Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Plasma Concentration (Cmax) After Single Dose of MSC2156119J: Regimen 1</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Plasma Concentration (Cmax) After Single Dose of MSC2156119J: Regimen 1</title>
          <population>Pharmacokinetic (PK) analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.62" spread="20.4"/>
                    <measurement group_id="O2" value="70.65" spread="19.3"/>
                    <measurement group_id="O3" value="107.0" spread="29.6"/>
                    <measurement group_id="O4" value="147.0" spread="24.0"/>
                    <measurement group_id="O5" value="193.8" spread="55.3"/>
                    <measurement group_id="O6" value="306.4" spread="42.2"/>
                    <measurement group_id="O7" value="348.1" spread="18.6"/>
                    <measurement group_id="O8" value="3.445" spread="104.5"/>
                    <measurement group_id="O9" value="12.64" spread="44.5"/>
                    <measurement group_id="O10" value="13.72" spread="142.0"/>
                    <measurement group_id="O11" value="13.38" spread="74.1"/>
                    <measurement group_id="O12" value="29.03" spread="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Plasma Concentration (Cmax) After Single Dose of MSC2156119J: Regimen 2</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Plasma Concentration (Cmax) After Single Dose of MSC2156119J: Regimen 2</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.55" spread="53.6"/>
                    <measurement group_id="O2" value="115.5" spread="59.3"/>
                    <measurement group_id="O3" value="134.8" spread="22.3"/>
                    <measurement group_id="O4" value="142.4" spread="58.9"/>
                    <measurement group_id="O5" value="333.7" spread="78.5"/>
                    <measurement group_id="O6" value="5.926" spread="102.3"/>
                    <measurement group_id="O7" value="10.79" spread="67.1"/>
                    <measurement group_id="O8" value="22.24" spread="141.0"/>
                    <measurement group_id="O9" value="37.42" spread="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Plasma Concentration (Cmax) After Single Dose of MSC2156119J: Regimen 3</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1200 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 1200 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 500 mg: Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Plasma Concentration (Cmax) After Single Dose of MSC2156119J: Regimen 3</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.5" spread="32.7"/>
                    <measurement group_id="O2" value="552.0">Geometric Coefficient of Variation could not be calculated as there was only 1 subject analyzed in this reporting group.</measurement>
                    <measurement group_id="O3" value="329.9" spread="72.4"/>
                    <measurement group_id="O4" value="433.5" spread="27.6"/>
                    <measurement group_id="O5" value="666.1" spread="46.0"/>
                    <measurement group_id="O6" value="761.0">Geometric Coefficient of Variation could not be calculated as there was only 1 subject analyzed in this reporting group.</measurement>
                    <measurement group_id="O7" value="863.4" spread="37.4"/>
                    <measurement group_id="O8" value="460.9" spread="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Plasma Concentration (Cmax) After Multiple Dose of MSC2156119J: Regimen 1</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Plasma Concentration (Cmax) After Multiple Dose of MSC2156119J: Regimen 1</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.6" spread="26.1"/>
                    <measurement group_id="O2" value="204.6" spread="24.2"/>
                    <measurement group_id="O3" value="262.8" spread="10.2"/>
                    <measurement group_id="O4" value="379.3" spread="19.8"/>
                    <measurement group_id="O5" value="697.2" spread="49.8"/>
                    <measurement group_id="O6" value="810.9" spread="12.3"/>
                    <measurement group_id="O7" value="562.5" spread="45.0"/>
                    <measurement group_id="O8" value="28.54" spread="181.7"/>
                    <measurement group_id="O9" value="59.76" spread="110.0"/>
                    <measurement group_id="O10" value="48.33" spread="102.8"/>
                    <measurement group_id="O11" value="155.6" spread="249.6"/>
                    <measurement group_id="O12" value="210.1" spread="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Plasma Concentration (Cmax) After Multiple Dose of MSC2156119J: Regimen 2</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 19 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Plasma Concentration (Cmax) After Multiple Dose of MSC2156119J: Regimen 2</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.55" spread="53.0"/>
                    <measurement group_id="O2" value="181.4" spread="34.4"/>
                    <measurement group_id="O3" value="178.4" spread="67.6"/>
                    <measurement group_id="O4" value="300.5" spread="8.9"/>
                    <measurement group_id="O5" value="722.4" spread="32.2"/>
                    <measurement group_id="O6" value="8.458" spread="339.9"/>
                    <measurement group_id="O7" value="54.30" spread="48.5"/>
                    <measurement group_id="O8" value="52.30" spread="140.7"/>
                    <measurement group_id="O9" value="70.04" spread="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Plasma Concentration (Cmax) After Multiple Dose of MSC2156119J: Regimen 3</title>
        <description>Reporting group &quot;MSC2156119J 1200 mg: Fasted&quot; is not applicable for Multiple Dosing because only one subject was erroneously dosed with 1200 mg in fasted state as a single dose in Regimen 3. For multiple dose PK profile (Study Day 14), this subject was included in reporting group &quot;MSC2156119J 1400 mg: Fed&quot;.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 500 mg: Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Plasma Concentration (Cmax) After Multiple Dose of MSC2156119J: Regimen 3</title>
          <description>Reporting group &quot;MSC2156119J 1200 mg: Fasted&quot; is not applicable for Multiple Dosing because only one subject was erroneously dosed with 1200 mg in fasted state as a single dose in Regimen 3. For multiple dose PK profile (Study Day 14), this subject was included in reporting group &quot;MSC2156119J 1400 mg: Fed&quot;.</description>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="741.6" spread="45.7"/>
                    <measurement group_id="O2" value="795.0">Geometric Coefficient of Variation could not be calculated as there was only 1 subject analyzed in this reporting group.</measurement>
                    <measurement group_id="O3" value="943.1" spread="34.6"/>
                    <measurement group_id="O4" value="1006" spread="39.4"/>
                    <measurement group_id="O5" value="1219" spread="59.2"/>
                    <measurement group_id="O6" value="1805" spread="31.2"/>
                    <measurement group_id="O7" value="1291" spread="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To Reach Maximum Plasma Concentration (Tmax) After Single Dose of MSC2156119J: Regimen 1</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Time To Reach Maximum Plasma Concentration (Tmax) After Single Dose of MSC2156119J: Regimen 1</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.000" lower_limit="2.00" upper_limit="24.05"/>
                    <measurement group_id="O2" value="10.000" lower_limit="8.00" upper_limit="24.00"/>
                    <measurement group_id="O3" value="10.000" lower_limit="4.00" upper_limit="24.00"/>
                    <measurement group_id="O4" value="8.000" lower_limit="8.00" upper_limit="10.00"/>
                    <measurement group_id="O5" value="8.000" lower_limit="4.00" upper_limit="24.00"/>
                    <measurement group_id="O6" value="10.000" lower_limit="4.10" upper_limit="24.00"/>
                    <measurement group_id="O7" value="8.000" lower_limit="8.00" upper_limit="10.05"/>
                    <measurement group_id="O8" value="4.000" lower_limit="4.00" upper_limit="10.00"/>
                    <measurement group_id="O9" value="8.000" lower_limit="8.00" upper_limit="24.00"/>
                    <measurement group_id="O10" value="10.000" lower_limit="4.00" upper_limit="24.00"/>
                    <measurement group_id="O11" value="24.000" lower_limit="8.00" upper_limit="25.65"/>
                    <measurement group_id="O12" value="8.000" lower_limit="4.00" upper_limit="24.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To Reach Maximum Plasma Concentration (Tmax) After Single Dose of MSC2156119J: Regimen 2</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24, 48, 49.32 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Time To Reach Maximum Plasma Concentration (Tmax) After Single Dose of MSC2156119J: Regimen 2</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.000" lower_limit="4.00" upper_limit="24.20"/>
                    <measurement group_id="O2" value="8.000" lower_limit="4.000" upper_limit="23.83"/>
                    <measurement group_id="O3" value="9.000" lower_limit="4.03" upper_limit="24.33"/>
                    <measurement group_id="O4" value="8.000" lower_limit="4.00" upper_limit="24.03"/>
                    <measurement group_id="O5" value="24.000" lower_limit="7.97" upper_limit="24.03"/>
                    <measurement group_id="O6" value="10.000" lower_limit="8.00" upper_limit="48.00"/>
                    <measurement group_id="O7" value="17.042" lower_limit="8.00" upper_limit="48.00"/>
                    <measurement group_id="O8" value="33.083" lower_limit="8.00" upper_limit="48.00"/>
                    <measurement group_id="O9" value="24.000" lower_limit="8.00" upper_limit="49.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To Reach Maximum Plasma Concentration (Tmax) After Single Dose of MSC2156119J: Regimen 3</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1200 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 1200 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 500 mg Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Time To Reach Maximum Plasma Concentration (Tmax) After Single Dose of MSC2156119J: Regimen 3</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.000" lower_limit="8.00" upper_limit="24.00"/>
                    <measurement group_id="O2" value="8.000" lower_limit="8.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="10.000" lower_limit="4.00" upper_limit="24.00"/>
                    <measurement group_id="O4" value="10.000" lower_limit="4.00" upper_limit="24.00"/>
                    <measurement group_id="O5" value="10.000" lower_limit="4.00" upper_limit="10.17"/>
                    <measurement group_id="O6" value="10.000" lower_limit="10.00" upper_limit="10.00"/>
                    <measurement group_id="O7" value="24.000" lower_limit="8.00" upper_limit="24.00"/>
                    <measurement group_id="O8" value="8.025" lower_limit="4.00" upper_limit="24.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To Reach Maximum Plasma Concentration (Tmax) After Multiple Dose of MSC2156119J: Regimen 1</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Time To Reach Maximum Plasma Concentration (Tmax) After Multiple Dose of MSC2156119J: Regimen 1</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.125" lower_limit="0.00" upper_limit="4.25"/>
                    <measurement group_id="O2" value="8.000" lower_limit="4.03" upper_limit="8.00"/>
                    <measurement group_id="O3" value="8.000" lower_limit="4.00" upper_limit="24.00"/>
                    <measurement group_id="O4" value="4.000" lower_limit="0.00" upper_limit="24.00"/>
                    <measurement group_id="O5" value="8.000" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O6" value="8.000" lower_limit="0.00" upper_limit="10.15"/>
                    <measurement group_id="O7" value="0.250" lower_limit="0.00" upper_limit="10.00"/>
                    <measurement group_id="O8" value="4.000" lower_limit="0.00" upper_limit="24.00"/>
                    <measurement group_id="O9" value="4.000" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O10" value="6.000" lower_limit="0.00" upper_limit="24.00"/>
                    <measurement group_id="O11" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O12" value="4.000" lower_limit="1.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To Reach Maximum Plasma Concentration (Tmax) After Multiple Dose of MSC2156119J: Regimen 2</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 19 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Time To Reach Maximum Plasma Concentration (Tmax) After Multiple Dose of MSC2156119J: Regimen 2</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.000" lower_limit="4.12" upper_limit="10.08"/>
                    <measurement group_id="O2" value="10.000" lower_limit="2.00" upper_limit="24.13"/>
                    <measurement group_id="O3" value="8.000" lower_limit="4.00" upper_limit="10.00"/>
                    <measurement group_id="O4" value="10.000" lower_limit="8.00" upper_limit="10.00"/>
                    <measurement group_id="O5" value="8.000" lower_limit="8.00" upper_limit="25.93"/>
                    <measurement group_id="O6" value="8.000" lower_limit="8.00" upper_limit="24.00"/>
                    <measurement group_id="O7" value="8.067" lower_limit="4.00" upper_limit="24.00"/>
                    <measurement group_id="O8" value="17.083" lower_limit="8.00" upper_limit="24.08"/>
                    <measurement group_id="O9" value="10.000" lower_limit="8.00" upper_limit="24.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To Reach Maximum Plasma Concentration (Tmax) After Multiple Dose of MSC2156119J: Regimen 3</title>
        <description>Reporting group &quot;MSC2156119J 1200 mg: Fasted&quot; is not applicable for Multiple Dosing because only one subject was erroneously dosed with 1200 mg in fasted state as a single dose in Regimen 3. For multiple dose PK profile (Study Day 14), this subject was included in reporting group &quot;MSC2156119J 1400 mg: Fed&quot;.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 500 mg: Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Time To Reach Maximum Plasma Concentration (Tmax) After Multiple Dose of MSC2156119J: Regimen 3</title>
          <description>Reporting group &quot;MSC2156119J 1200 mg: Fasted&quot; is not applicable for Multiple Dosing because only one subject was erroneously dosed with 1200 mg in fasted state as a single dose in Regimen 3. For multiple dose PK profile (Study Day 14), this subject was included in reporting group &quot;MSC2156119J 1400 mg: Fed&quot;.</description>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.000" lower_limit="0.50" upper_limit="10.00"/>
                    <measurement group_id="O2" value="10.000" lower_limit="10.00" upper_limit="10.00"/>
                    <measurement group_id="O3" value="8.000" lower_limit="0.00" upper_limit="24.00"/>
                    <measurement group_id="O4" value="3.183" lower_limit="0.25" upper_limit="8.00"/>
                    <measurement group_id="O5" value="8.833" lower_limit="0.00" upper_limit="24.00"/>
                    <measurement group_id="O6" value="9.075" lower_limit="2.83" upper_limit="24.00"/>
                    <measurement group_id="O7" value="8.000" lower_limit="2.00" upper_limit="24.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life ( t1/2) After Single Dose Of MSC2156119J: Regimen 1</title>
        <description>Apparent Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of t1/2.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life ( t1/2) After Single Dose Of MSC2156119J: Regimen 1</title>
          <description>Apparent Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of t1/2.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life ( t1/2) After Single Dose Of MSC2156119J: Regimen 2</title>
        <description>Apparent Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of t1/2.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life ( t1/2) After Single Dose Of MSC2156119J: Regimen 2</title>
          <description>Apparent Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of t1/2.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life ( t1/2) After Single Dose Of MSC2156119J: Regimen 3</title>
        <description>Apparent Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of t1/2.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1200 mg Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 1200 mg in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 1400 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 500 mg Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life ( t1/2) After Single Dose Of MSC2156119J: Regimen 3</title>
          <description>Apparent Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of t1/2.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life (t1/2) After Multiple Dose Of MSC2156119J: Regimen 1</title>
        <description>Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of t1/2.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) After Multiple Dose Of MSC2156119J: Regimen 1</title>
          <description>Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of t1/2.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life (t1/2) After Multiple Dose Of MSC2156119J: Regimen 2</title>
        <description>Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 19 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of t1/2.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) After Multiple Dose Of MSC2156119J: Regimen 2</title>
          <description>Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of t1/2.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life (t1/2) After Multiple Dose Of MSC2156119J: Regimen 3</title>
        <description>Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of t1/2.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 500 mg: Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) After Multiple Dose Of MSC2156119J: Regimen 3</title>
          <description>Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of t1/2.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration Versus Time Curve From Time Zero to Last Sampling Time (AUC0-t) After First Dose of MSC2156119J: Regimen 1</title>
        <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Versus Time Curve From Time Zero to Last Sampling Time (AUC0-t) After First Dose of MSC2156119J: Regimen 1</title>
          <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="849.4" spread="24.5"/>
                    <measurement group_id="O2" value="1283.0" spread="23.9"/>
                    <measurement group_id="O3" value="1433.5" spread="35.5"/>
                    <measurement group_id="O4" value="2532.7" spread="12.6"/>
                    <measurement group_id="O5" value="3105.5" spread="60.3"/>
                    <measurement group_id="O6" value="5467.9" spread="49.9"/>
                    <measurement group_id="O7" value="6176.3" spread="17.8"/>
                    <measurement group_id="O8" value="41.6" spread="288.7"/>
                    <measurement group_id="O9" value="218.8" spread="38.5"/>
                    <measurement group_id="O10" value="215.0" spread="163.5"/>
                    <measurement group_id="O11" value="225.6" spread="88.7"/>
                    <measurement group_id="O12" value="516.5" spread="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After First Dose of MSC2156119J: Regimen 2</title>
        <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After First Dose of MSC2156119J: Regimen 2</title>
          <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1771.5" spread="43.1"/>
                    <measurement group_id="O2" value="3665.3" spread="41.9"/>
                    <measurement group_id="O3" value="3794.2" spread="32.1"/>
                    <measurement group_id="O4" value="4659.6" spread="44.9"/>
                    <measurement group_id="O5" value="10818.0" spread="48.9"/>
                    <measurement group_id="O6" value="206.9" spread="92.6"/>
                    <measurement group_id="O7" value="310.5" spread="27.6"/>
                    <measurement group_id="O8" value="745.3" spread="130.8"/>
                    <measurement group_id="O9" value="1323.5" spread="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After First Dose of MSC2156119J: Regimen 3</title>
        <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1200 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 1200 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 500 mg: Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After First Dose of MSC2156119J: Regimen 3</title>
          <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4209.3" spread="33.4"/>
                    <measurement group_id="O2" value="3190.8">Geometric Coefficient of Variation could not be calculated as there was only 1 subject analyzed in this reporting group.</measurement>
                    <measurement group_id="O3" value="5667.3" spread="76.1"/>
                    <measurement group_id="O4" value="4980.9" spread="86.3"/>
                    <measurement group_id="O5" value="10355.6" spread="59.6"/>
                    <measurement group_id="O6" value="13352.6">Geometric Coefficient of Variation could not be calculated as there was only 1 subject analyzed in this reporting group.</measurement>
                    <measurement group_id="O7" value="15542.0" spread="41.9"/>
                    <measurement group_id="O8" value="7661.8" spread="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After Multiple Dose of MSC2156119J : Regimen 1</title>
        <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After Multiple Dose of MSC2156119J : Regimen 1</title>
          <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7532.7" spread="19.1"/>
                    <measurement group_id="O2" value="14113.2" spread="32.1"/>
                    <measurement group_id="O3" value="18334.0" spread="19.4"/>
                    <measurement group_id="O4" value="18409.6" spread="14.3"/>
                    <measurement group_id="O5" value="56102.4" spread="73.7"/>
                    <measurement group_id="O6" value="82253.4" spread="10.1"/>
                    <measurement group_id="O7" value="44598.2" spread="80.7"/>
                    <measurement group_id="O8" value="2008.0" spread="344.0"/>
                    <measurement group_id="O9" value="4483.4" spread="284.9"/>
                    <measurement group_id="O10" value="3555.4" spread="116.3"/>
                    <measurement group_id="O11" value="4234.1" spread="40.3"/>
                    <measurement group_id="O12" value="13872.2" spread="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After Multiple Dose of MSC2156119J : Regimen 2</title>
        <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 19 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After Multiple Dose of MSC2156119J : Regimen 2</title>
          <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.</description>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4079.6" spread="71.1"/>
                    <measurement group_id="O2" value="5079.7" spread="116.0"/>
                    <measurement group_id="O3" value="4962.0" spread="33.3"/>
                    <measurement group_id="O4" value="7963.8" spread="34.0"/>
                    <measurement group_id="O5" value="36701.1" spread="26.1"/>
                    <measurement group_id="O6" value="375.2" spread="278.2"/>
                    <measurement group_id="O7" value="2056.6" spread="31.4"/>
                    <measurement group_id="O8" value="2562.0" spread="78.9"/>
                    <measurement group_id="O9" value="2899.0" spread="132.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After Multiple Dose of MSC2156119J : Regimen 3</title>
        <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. Reporting group &quot;MSC2156119J 1200 mg: Fasted&quot; is not applicable for Multiple Dosing because only one subject was erroneously dosed with 1200 mg in fasted state as a single dose in Regimen 3. For multiple dose PK profile (Study Day 14), this subject was included in reporting group &quot;MSC2156119J 1400 mg: Fed&quot;.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 500 mg: Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time (AUC0-t) After Multiple Dose of MSC2156119J : Regimen 3</title>
          <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the LLQ. AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. Reporting group &quot;MSC2156119J 1200 mg: Fasted&quot; is not applicable for Multiple Dosing because only one subject was erroneously dosed with 1200 mg in fasted state as a single dose in Regimen 3. For multiple dose PK profile (Study Day 14), this subject was included in reporting group &quot;MSC2156119J 1400 mg: Fed&quot;.</description>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15694.9" spread="50.8"/>
                    <measurement group_id="O2" value="17498.1">Geometric Coefficient of Variation could not be calculated as there was only 1 subject analyzed in this reporting group.</measurement>
                    <measurement group_id="O3" value="20210.4" spread="33.5"/>
                    <measurement group_id="O4" value="17107.8" spread="3.2"/>
                    <measurement group_id="O5" value="27716.9" spread="58.6"/>
                    <measurement group_id="O6" value="39730.6" spread="29.5"/>
                    <measurement group_id="O7" value="18915.7" spread="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) After Single Dose Of MSC2156119J: Regimen 1</title>
        <description>AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of AUC0-inf.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) After Single Dose Of MSC2156119J: Regimen 1</title>
          <description>AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of AUC0-inf.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) After Single Dose Of MSC2156119J: Regimen 2</title>
        <description>AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of AUC0-inf.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) After Single Dose Of MSC2156119J: Regimen 2</title>
          <description>AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of AUC0-inf.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) After Single Dose Of MSC2156119J: Regimen 3</title>
        <description>AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of AUC0-inf.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg with food</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg with food</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1200 mg Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 1200 mg in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 1400 mg Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 500 mg Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (Tablet) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) After Single Dose Of MSC2156119J: Regimen 3</title>
          <description>AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of AUC0-inf.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Single Dose of MSC2156119: Regimen 1</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Single Dose of MSC2156119: Regimen 1</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="848.7" spread="24.3"/>
                    <measurement group_id="O2" value="1283.0" spread="23.9"/>
                    <measurement group_id="O3" value="1731.3" spread="14.9"/>
                    <measurement group_id="O4" value="2454.5" spread="15.4"/>
                    <measurement group_id="O5" value="3090.2" spread="61.2"/>
                    <measurement group_id="O6" value="5462.8" spread="49.9"/>
                    <measurement group_id="O7" value="6176.3" spread="17.8"/>
                    <measurement group_id="O8" value="94.0" spread="66.2"/>
                    <measurement group_id="O9" value="218.8" spread="38.5"/>
                    <measurement group_id="O10" value="259.3" spread="170.5"/>
                    <measurement group_id="O11" value="220.6" spread="93.4"/>
                    <measurement group_id="O12" value="515.3" spread="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Single Dose of MSC2156119: Regimen 2</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24, 48 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Single Dose of MSC2156119: Regimen 2</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1771.5" spread="43.1"/>
                    <measurement group_id="O2" value="3657.3" spread="42.0"/>
                    <measurement group_id="O3" value="3794.2" spread="32.1"/>
                    <measurement group_id="O4" value="4659.6" spread="44.9"/>
                    <measurement group_id="O5" value="10786.4" spread="49.4"/>
                    <measurement group_id="O6" value="206.9" spread="92.6"/>
                    <measurement group_id="O7" value="306.1" spread="33.9"/>
                    <measurement group_id="O8" value="626.0" spread="96.5"/>
                    <measurement group_id="O9" value="1317.0" spread="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Single Dose of MSC2156119: Regimen 3</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1200 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 1200 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 500 mg: Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Single Dose of MSC2156119: Regimen 3</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4206.5" spread="33.5"/>
                    <measurement group_id="O2" value="NA">Data were not reported to reduce misunderstanding as 1 subject in “MSC2156119J 500 mg: Fasted arm” either took a wrong dose or intake was performed with a wrong mode of administration.</measurement>
                    <measurement group_id="O3" value="5917.9" spread="74.8"/>
                    <measurement group_id="O4" value="7575.8" spread="24.6"/>
                    <measurement group_id="O5" value="11796.4" spread="48.1"/>
                    <measurement group_id="O6" value="NA">Data were not reported to reduce misunderstanding as 1 subject in “MSC2156119J 1200 mg: Fasted arm” either took a wrong dose or intake was performed with a wrong mode of administration.</measurement>
                    <measurement group_id="O7" value="15542.0" spread="41.9"/>
                    <measurement group_id="O8" value="7637.3" spread="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Multiple Dose of MSC2156119: Regimen 1</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Multiple Dose of MSC2156119: Regimen 1</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2266.7" spread="29.5"/>
                    <measurement group_id="O2" value="4443.1" spread="28.1"/>
                    <measurement group_id="O3" value="5499.6" spread="7.0"/>
                    <measurement group_id="O4" value="8099.6" spread="18.0"/>
                    <measurement group_id="O5" value="13938.4" spread="50.9"/>
                    <measurement group_id="O6" value="18276.5" spread="12.4"/>
                    <measurement group_id="O7" value="12256.8" spread="49.1"/>
                    <measurement group_id="O8" value="585.3" spread="158.4"/>
                    <measurement group_id="O9" value="1241.2" spread="132.2"/>
                    <measurement group_id="O10" value="1011.1" spread="110.3"/>
                    <measurement group_id="O11" value="1434.2" spread="14.3"/>
                    <measurement group_id="O12" value="4658.2" spread="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Multiple Dose of MSC2156119: Regimen 2</title>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24, 48 hours post-dose on Day 19 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Multiple Dose of MSC2156119: Regimen 2</title>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3031.7" spread="55.8"/>
                    <measurement group_id="O2" value="7565.6" spread="35.0"/>
                    <measurement group_id="O3" value="5305.5" spread="62.6"/>
                    <measurement group_id="O4" value="9051.1">Geometric Coefficient of Variation could not be calculated as there was only 1 subject analyzed in this reporting group.</measurement>
                    <measurement group_id="O5" value="27760.2" spread="25.1"/>
                    <measurement group_id="O6" value="273.7" spread="909.0"/>
                    <measurement group_id="O7" value="2054.1" spread="33.3"/>
                    <measurement group_id="O8" value="1634.4" spread="103.5"/>
                    <measurement group_id="O9" value="3538.9" spread="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Multiple Dose of MSC2156119: Regimen 3</title>
        <description>Reporting group &quot;MSC2156119J 1200 mg: Fasted&quot; is not applicable for Multiple Dosing because only one subject was erroneously dosed with 1200 mg in fasted state as a single dose in Regimen 3. For multiple dose PK profile (Study Day 14), this subject was included in reporting group &quot;MSC2156119J 1400 mg: Fed&quot;.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 500 mg: Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau) After Multiple Dose of MSC2156119: Regimen 3</title>
          <description>Reporting group &quot;MSC2156119J 1200 mg: Fasted&quot; is not applicable for Multiple Dosing because only one subject was erroneously dosed with 1200 mg in fasted state as a single dose in Regimen 3. For multiple dose PK profile (Study Day 14), this subject was included in reporting group &quot;MSC2156119J 1400 mg: Fed&quot;.</description>
          <population>PK analysis set included all subjects who had received at least 1 dose of MSC2156119J and who had provided at least 1 concentration of MSC2156119J measurement after the first dose. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15597.6" spread="50.0"/>
                    <measurement group_id="O2" value="17498.1">Geometric Coefficient of Variation could not be calculated as there was only 1 subject analyzed in this reporting group.</measurement>
                    <measurement group_id="O3" value="20169.3" spread="33.5"/>
                    <measurement group_id="O4" value="21972.2" spread="42.9"/>
                    <measurement group_id="O5" value="27214.4" spread="59.4"/>
                    <measurement group_id="O6" value="39283.7" spread="28.0"/>
                    <measurement group_id="O7" value="27437.7" spread="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Body Clearance (CL/f) After First Dose of MSC2156119J: Regimen 1</title>
        <description>Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0−inf.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of CL/f.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Body Clearance (CL/f) After First Dose of MSC2156119J: Regimen 1</title>
          <description>Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0−inf.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of CL/f.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Body Clearance (CL/f) After First Dose of MSC2156119J: Regimen 2</title>
        <description>Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0−inf.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of CL/f.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Body Clearance (CL/f) After First Dose of MSC2156119J: Regimen 2</title>
          <description>Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0−inf.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of CL/f.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Body Clearance (CL/f) After First Dose of MSC2156119J: Regimen 3</title>
        <description>Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0−inf.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of CL/f.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1200 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 1200 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 500 mg: Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Body Clearance (CL/f) After First Dose of MSC2156119J: Regimen 3</title>
          <description>Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0−inf.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of CL/f.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/f) After First Dose of MSC2156119J: Regimen 1</title>
        <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of Vz/f.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/f) After First Dose of MSC2156119J: Regimen 1</title>
          <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of Vz/f.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/f) After First Dose of MSC2156119J: Regimen 2</title>
        <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of Vz/f.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/f) After First Dose of MSC2156119J: Regimen 2</title>
          <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of Vz/f.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/f) After First Dose of MSC2156119J: Regimen 3</title>
        <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of Vz/f.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1200 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 1200 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 500 mg Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/f) After First Dose of MSC2156119J: Regimen 3</title>
          <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of Vz/f.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/f) After Multiple Dose of MSC2156119J: Regimen 1</title>
        <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of Vz/f.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/f) After Multiple Dose of MSC2156119J: Regimen 1</title>
          <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of Vz/f.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/f) After Multiple Dose of MSC2156119J: Regimen 2</title>
        <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 19 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of Vz/f.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/f) After Multiple Dose of MSC2156119J: Regimen 2</title>
          <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of Vz/f.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/f) After Multiple Dose of MSC2156119J: Regimen 3</title>
        <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of Vz/f.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 500 mg: Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/f) After Multiple Dose of MSC2156119J: Regimen 3</title>
          <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant, which is needed for the calculation of Vz/f.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Rate Constant (λz) After Single Dose of MSC2156119J: Regimen 1</title>
        <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Rate Constant (λz) After Single Dose of MSC2156119J: Regimen 1</title>
          <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Rate Constant (λz) After Single Dose of MSC2156119J: Regimen 2</title>
        <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Rate Constant (λz) After Single Dose of MSC2156119J: Regimen 2</title>
          <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Rate Constant (λz) After Single Dose of MSC2156119J: Regimen 3</title>
        <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 1 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1200 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 1200 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 500 mg: Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Rate Constant (λz) After Single Dose of MSC2156119J: Regimen 3</title>
          <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Rate Constant (λz) After Multiple Dose of MSC2156119J: Regimen 1</title>
        <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 30 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 30 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 145 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 145 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 215 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 215 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O10">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O11">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O12">
            <title>MSC2156119J 230 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 230 mg (capsule formulation) in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Rate Constant (λz) After Multiple Dose of MSC2156119J: Regimen 1</title>
          <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Rate Constant (λz) After Multiple Dose of MSC2156119J: Regimen 2</title>
        <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 19 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 60 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 60 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 100 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 100 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 130 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 130 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 175 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 175 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 315 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 315 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 30 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 30 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 60 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 60 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O8">
            <title>MSC2156119J 115 mg: Fasted</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O9">
            <title>MSC2156119J 115 mg: Fed</title>
            <description>Subjects were administered with non-micronized MSC2156119J 115 mg (capsule formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Rate Constant (λz) After Multiple Dose of MSC2156119J: Regimen 2</title>
          <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Rate Constant (λz) After Multiple Dose of MSC2156119J: Regimen 3</title>
        <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
        <time_frame>pre-dose, 0.25, 0.5, 1, 2, 4, 8, 10, 24 hours post-dose on Day 14 Cycle 1</time_frame>
        <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J 300 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 300 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J 500 mg: Fasted</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J 500 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O4">
            <title>MSC2156119J 700 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 700 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O5">
            <title>MSC2156119J 1000 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1000 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O6">
            <title>MSC2156119J 1400 mg: Fed</title>
            <description>Subjects were administered with micronized MSC2156119J 1400 mg (capsule formulation) with food.</description>
          </group>
          <group group_id="O7">
            <title>MSC2156119J 500 mg: Fed (Tablet)</title>
            <description>Subjects were administered with micronized MSC2156119J 500 mg (tablet formulation) with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Rate Constant (λz) After Multiple Dose of MSC2156119J: Regimen 3</title>
          <description>Apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
          <population>It was not possible to calculate data for this outcome measure because dosing interval was too small compared to the long half-life to characterize the terminal phase rate constant.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Cytoplasm and Membrane H-Score at Day 1 Cycle 2</title>
        <description>Histo score (H-score) is a composite score that comprises of intensity and percentage of staining and is used for assessing the amount of protein or phospho-protein present in a biopsy sample. The composite score obtained by H-score is derived by summing the percentages of cell staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+; where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). The composite H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.</description>
        <time_frame>Baseline, Day 1 Cycle 2</time_frame>
        <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J Regimen 1</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J Regimen 2</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J Regimen 3</title>
            <description>Subjects were administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Cytoplasm and Membrane H-Score at Day 1 Cycle 2</title>
          <description>Histo score (H-score) is a composite score that comprises of intensity and percentage of staining and is used for assessing the amount of protein or phospho-protein present in a biopsy sample. The composite score obtained by H-score is derived by summing the percentages of cell staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+; where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). The composite H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.</description>
          <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment. Here, “Number of Participants Analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cytoplasm H-Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.94" spread="84.614"/>
                    <measurement group_id="O2" value="-31.43" spread="92.967"/>
                    <measurement group_id="O3" value="5.00" spread="72.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Membrane H-Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" spread="123.184"/>
                    <measurement group_id="O2" value="28.10" spread="75.407"/>
                    <measurement group_id="O3" value="-10.00" spread="75.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change From Baseline in Cytoplasm and Membrane H-Score at Day 1 Cycle 2</title>
        <description>Histo score (H-score) is a composite score that comprises of intensity and percentage of staining and is used for assessing the amount of protein or phospho-protein present in a biopsy sample. The composite score obtained by H-score is derived by summing the percentages of cell staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+; where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). The composite H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein. Fold change = on-treatment value/ baseline value</description>
        <time_frame>Baseline, Day 1 Cycle 2</time_frame>
        <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment. Here “Number of Participants analyzed” signifies those subjects who were evaluable for this outcome and “n” signifies those subjects who were evaluable in the specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J Regimen 1</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J Regimen 2</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J Regimen 3</title>
            <description>Subjects were administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change From Baseline in Cytoplasm and Membrane H-Score at Day 1 Cycle 2</title>
          <description>Histo score (H-score) is a composite score that comprises of intensity and percentage of staining and is used for assessing the amount of protein or phospho-protein present in a biopsy sample. The composite score obtained by H-score is derived by summing the percentages of cell staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+; where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). The composite H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein. Fold change = on-treatment value/ baseline value</description>
          <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment. Here “Number of Participants analyzed” signifies those subjects who were evaluable for this outcome and “n” signifies those subjects who were evaluable in the specified category for each arm, respectively.</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cytoplasm H-Score (n=16, 17, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.577"/>
                    <measurement group_id="O2" value="1.09" spread="0.570"/>
                    <measurement group_id="O3" value="1.12" spread="0.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Membrane H-Score (n= 0, 4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Fold change could not be calculated as there were no subjects with H-score baseline value of greater than 0.</measurement>
                    <measurement group_id="O2" value="1.29" spread="0.934"/>
                    <measurement group_id="O3" value="1.23" spread="0.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Monovalent Antagonist Antibody to Receptor MET (MetMAb) Score (MMS)</title>
        <description>MetMAb score was used to assess the tumor c-Met expression and ranged from 0 to 3, where a score of 0 corresponds to the lowest c-Met expression and a score of 3 corresponds to the highest c-Met expression in tumor tissue by immunohistochemistry.</description>
        <time_frame>Day 1 Cycle 2</time_frame>
        <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J Regimen 1</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J Regimen 2</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J Regimen 3</title>
            <description>Subjects were administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Monovalent Antagonist Antibody to Receptor MET (MetMAb) Score (MMS)</title>
          <description>MetMAb score was used to assess the tumor c-Met expression and ranged from 0 to 3, where a score of 0 corresponds to the lowest c-Met expression and a score of 3 corresponds to the highest c-Met expression in tumor tissue by immunohistochemistry.</description>
          <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMS Score 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMS Score 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMS Score 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMS Score 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMS Score Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Percentage Change In Sum of Longest Diameter (SOLD) of Target Lesions to Post-Baseline Nadir</title>
        <description>The post-baseline nadir was defined as the the smallest SOLD recorded after baseline. The relative change (%) was derived based on the SOLD of target lesions as follows: 100* (SOLD at post-baseline nadir - baseline SOLD) / baseline SOLD.</description>
        <time_frame>Baseline, On Treatment (up to 153.3 weeks)</time_frame>
        <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment. Here “Number of Participants Analyzed” signifies those subjects who presented a measurable tumor at baseline and at least one post-baseline tumor assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J Regimen 1</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J Regimen 2</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J Regimen 3</title>
            <description>Subjects were administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Percentage Change In Sum of Longest Diameter (SOLD) of Target Lesions to Post-Baseline Nadir</title>
          <description>The post-baseline nadir was defined as the the smallest SOLD recorded after baseline. The relative change (%) was derived based on the SOLD of target lesions as follows: 100* (SOLD at post-baseline nadir - baseline SOLD) / baseline SOLD.</description>
          <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment. Here “Number of Participants Analyzed” signifies those subjects who presented a measurable tumor at baseline and at least one post-baseline tumor assessment.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.67" spread="28.738"/>
                    <measurement group_id="O2" value="16.19" spread="22.055"/>
                    <measurement group_id="O3" value="18.87" spread="39.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Best Overall Response (BOR)</title>
        <description>Number of subjects with BOR in each category (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD]) according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) was reported. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. PD:defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study.</description>
        <time_frame>Baseline up to 153.3 weeks</time_frame>
        <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J Regimen 1</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J Regimen 2</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J Regimen 3</title>
            <description>Subjects were administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Best Overall Response (BOR)</title>
          <description>Number of subjects with BOR in each category (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD]) according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) was reported. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. PD:defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study.</description>
          <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS was defined as the time (in months) between the first dosing day and radiographic PD or clinical PD (as recorded on the study termination form) or death, if death occurred within 12 weeks (84 days) after the last tumor assessment without documented progressive disease, whichever occurred first. Any subject with neither assessment of tumor progression, nor death within 12 weeks after last tumor assessment date was censored on the date of last tumor assessment.</description>
        <time_frame>Baseline up to 153.3 weeks</time_frame>
        <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment. Here, &quot;Number of Participants Analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSC2156119J Regimen 1</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
          </group>
          <group group_id="O2">
            <title>MSC2156119J Regimen 2</title>
            <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
          </group>
          <group group_id="O3">
            <title>MSC2156119J Regimen 3</title>
            <description>Subjects were administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS was defined as the time (in months) between the first dosing day and radiographic PD or clinical PD (as recorded on the study termination form) or death, if death occurred within 12 weeks (84 days) after the last tumor assessment without documented progressive disease, whichever occurred first. Any subject with neither assessment of tumor progression, nor death within 12 weeks after last tumor assessment date was censored on the date of last tumor assessment.</description>
          <population>Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment. Here, &quot;Number of Participants Analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.3" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.2" upper_limit="1.3"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.3" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 158.01 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MSC2156119J Regimen 1</title>
          <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.</description>
        </group>
        <group group_id="E2">
          <title>MSC2156119J Regimen 2</title>
          <description>Subjects were administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.</description>
        </group>
        <group group_id="E3">
          <title>MSC2156119J Regimen 3</title>
          <description>Subjects were administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MESENTERIC VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DEVICE OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>JAUNDICE CHOLESTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>TRACHEOBRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>WAIST CIRCUMFERENCE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>METASTASES TO CENTRAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>TUMOUR HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VAGUS NERVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>JUGULAR VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SUPERIOR VENA CAVA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ANAEMIA OF CHRONIC DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HAEMOLYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SINUS ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>EAR DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>EAR SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MIDDLE EAR EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BASEDOW’S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>THYROID DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LACRIMATION INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BLEPHAROSPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RETINAL PIGMENT EPITHELIOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VITREOUS FLOATERS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ABDOMINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>CHANGE OF BOWEL HABIT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ERUCTATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>FAECAL INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>FAECES DISCOLOURED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL MOTILITY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL SOUNDS ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GINGIVAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LIP SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NEUROGENIC BOWEL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ODYNOPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RETCHING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>AXILLARY PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>EARLY SATIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LOCAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>CATHETER SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>FEELING COLD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LOCALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SENSATION OF FOREIGN BODY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PORTAL VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY TO ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HORDEOLUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>INFECTED FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NAIL BED INFECTION FUNGAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ONYCHOMYCOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PAROTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>EPICONDYLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>FEEDING TUBE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NAIL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RADIATION PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>STOMA SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LIPASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BREATH SOUNDS ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>AMYLASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PROSTATIC SPECIFIC ANTIGEN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ANTICOAGULATION DRUG LEVEL BELOW THERAPEUTIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BLOOD LACTATE DEHYDROGENASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE DIASTOLIC ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BLOOD UREA INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM PR SHORTENED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST SEGMENT ELEVATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HAEMATOCRIT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PEDAL PULSE ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>WAIST CIRCUMFERENCE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>CACHEXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPERPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DYSLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PAIN IN JAW</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GROIN PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>JOINT ANKYLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>SEBORRHOEIC KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>TUMOUR HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>TUMOUR INVASION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>AKATHISIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BALANCE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DIZZINESS POSTURAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DYSKINESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VOCAL CORD PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>EMOTIONAL DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>FLAT AFFECT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>CHROMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>GLYCOSURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NEUROGENIC BLADDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NOCTURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>POLLAKIURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RENAL ATROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RENAL HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>URETERIC OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>URINARY HESITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>SCROTAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NIPPLE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VAGINAL DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BREAST MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BREAST SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BREAST TENDERNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DYSPAREUNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NIPPLE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PENILE OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SCROTAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>TESTICULAR SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>TACHYPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PHOTOSENSITIVITY REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RASH ERYTHEMATOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RASH VESICULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SKIN HYPERPIGMENTATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SWELLING FACE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ACTINIC KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>BLISTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DERMATITIS ACNEIFORM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPERKERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>INGROWING NAIL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ONYCHOCLASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ONYCHOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RASH GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SKIN EXFOLIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SKIN MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>STASIS DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It was not possible to calculate data for PK parameters such as t1/2, AUC0-inf, CL/f, Vz/f, λz because dosing interval was too small compared to the long half-life to characterize terminal phase rate constant, which is needed for the calculation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Healthcare, a business of Merck KGaA, Darmstadt, Germany</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

